J&J vs. Merck: The Race Is On As Incivek Passes First EU Regulatory Hurdle

Merck's Victrelis is still likely to have a marketing advantage of one to two months over J&J's Incivek in the EU hepatitis C market, but pricing and reimbursement issues in the Member States will probably drive market share more than anything else.